13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q1 2024. See the latest, Q2 2026 →
Reported value
$4.47B
+13% on the quarter before
Positions
363
180 new · 180 sold out
Top 10
23.4%
of the value
Est. gain
+$89.6M
on stocks held all quarter
Est. return
+4.8%
on those stocks since Q4 2023
Positions as of Mar 31, 2024, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 46% of the reported value, each sized by its share, colored by what the fund did with it since Q4 2023. Striped tiles are options.
Largest buys
Since Q4 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Southwestern Energy Co~$91.1MAdded · 0.1% → 2.1%+12,013,898 shares
- M D C Hldgs Inc~$87.6MNew · 0.0% → 2.0%+1,392,641 shares
- Juniper Networks Inc~$86.5MNew · 0.0% → 1.9%+2,333,884 shares
- Mcgrath Rentcorp~$84.0MNew · 0.0% → 1.9%+681,216 shares
- Enerplus Corp~$81.9MNew · 0.0% → 1.8%+4,168,212 shares
- Becton Dickinson & Co~$75.5MNew · 0.0% → 1.7%+305,084 shares
- Ansys Inc~$72.8MNew · 0.0% → 1.6%+209,694 shares
- Discover Finl Svcs~$71.7MNew · 0.0% → 1.6%+546,896 shares
- Medtronic Plc~$66.4MAdded · 1.3% → 2.7%+761,368 shares
- Novartis Ag~$64.4MAdded · 3.2% → 4.1%+666,104 shares
Largest sells
Since Q4 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Humana Inc~$160.1MSold out · 4.1% → 0.0%−349,813 shares
- Merck & Co Inc~$157.5MCut · 3.9% → 0.6%−1,193,315 shares
- Splunk Inc~$83.2MSold out · 2.1% → 0.0%−546,078 shares
- Pnm Res Inc~$83.0MSold out · 2.1% → 0.0%−1,994,913 shares
- Encompass Health Corp~$72.2MCut · 2.1% → 0.7%−874,727 shares
- Karuna Therapeutics Inc~$64.0MSold out · 1.6% → 0.0%−202,165 shares
- Cytokinetics Inc~$54.5MSold out · 1.4% → 0.0%−30,850,000 shares
- Mirati Therapeutics Inc~$49.0MSold out · 1.2% → 0.0%−834,390 shares
- Immunogen Inc~$48.3MSold out · 1.2% → 0.0%−1,629,285 shares
- Abbott Labs~$37.4MCut · 2.3% → 1.2%−329,380 shares
Holdings
As of Mar 31, 2024. Changes are in shares against Dec 31, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis AgSPONSORED ADR · shares +54% · price −4.2% | 4.1% | $184.4M | −$5.3M | ||||||||
| Medtronic PlcSHS · shares +120% · price +5.8% | 2.7% | $121.5M | +$3.0M | ||||||||
| Zimmer Biomet Holdings IncCOM · shares +12% · price +8.4% | 2.4% | $108.9M | +$7.6M | ||||||||
| Southwestern Energy CoCOM · shares +3,468% · price +15.7% | 2.1% | $93.7M | +$356,780 | ||||||||
| Pioneer Nat Res CoCOM · shares −4.7% · price +16.7% | 2.1% | $92.6M | +$13.3M | ||||||||
| Globus MedicalCL A · shares +199% · price +0.7% | 2.0% | $90.6M | +$198,011 | ||||||||
| Westrock CoCOM · shares −14% · price +19.1% | 2.0% | $89.9M | +$14.4M | ||||||||
| Churchill Capital Corp ViiCOM CL A · shares −0.00% · price +1.9% | 2.0% | $88.9M | +$1.7M | ||||||||
| M D C Hldgs IncCOM · shares New | 2.0% | $87.6M | — | ||||||||
| Juniper Networks IncCOM · shares New | 1.9% | $86.5M | — | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares 0% · price −6.8% | 1.9% | $84.4M | −$6.1M | ||||||||
| Elanco Animal Health IncCOM · shares −11% · price +9.3% | 1.9% | $84.2M | +$7.1M | ||||||||
| Mcgrath RentcorpCOM · shares New | 1.9% | $84.0M | — | ||||||||
| Enerplus CorpCOM · shares New | 1.8% | $81.9M | — | ||||||||
| Axonics IncCOM · shares +218% · price +10.8% | 1.8% | $79.0M | +$2.4M | ||||||||
| Becton Dickinson & CoCOM · shares New | 1.7% | $75.5M | — | ||||||||
| Ansys IncCOM · shares New | 1.6% | $72.8M | — | ||||||||
| Discover Finl SvcsCOM · shares New | 1.6% | $71.7M | — | ||||||||
| Gsk PlcSPONSORED ADR · shares +17% · price +15.7% | 1.6% | $70.8M | +$8.2M | ||||||||
| Masonite Intl CorpCOM · shares New | 1.3% | $59.8M | — | ||||||||
| Astrazeneca PlcSPONSORED ADR · shares +648% · price +0.6% | 1.3% | $59.7M | +$47,128 | ||||||||
| The Cigna GroupCOM · shares −15% · price +21.3% | 1.3% | $59.3M | +$10.4M | ||||||||
| Amedisys IncCOM · shares 0% · price −3.1% | 1.3% | $57.0M | −$1.8M | ||||||||
| Catalent IncCOM · shares New | 1.3% | $56.4M | — | ||||||||
| Mckesson CorpCOM · shares −20% · price +16.0% | 1.2% | $55.8M | +$7.7M | ||||||||
| Total · 363 positions | 100% | $4.47B | +$89.6M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2023 to Q1 2024: 147 stocks held throughout, up $89.6M (+4.8%).
- Westrock Co+$14.4M+19%
- Pioneer Nat Res Co+$13.3M+17%
- The Cigna Group+$10.4M+21%
- Adma Biologics Inc+$9.7M+46%
- Gsk Plc+$8.2M+16%
- Novartis Ag−$5.3M−4%
- Capri Holdings Limited−$5.6M−10%
- Albertsons Cos Inc−$6.1M−7%
- United States Stl Corp New−$6.2M−16%
- Brooge Energy Ltd−$9.7M−40%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |